The uterus is the most recent addition to the list of organs that can be successfully transplanted in humans. This article analyzes living donor uterus transplantation according to the ethical principle of equipoise. A comparison is made between living donor uterus transplantation and gestational surrogate motherhood. Both are solutions to absolute uterine infertility that allow the transfer of genetic material from intended parents to a child. The analysis concludes that living donor uterus transplantation does not violate the ethical principle of equipoise and should be considered an ethically acceptable solution to absolute uterine infertility.
Abbreviations: AUI, absolute uterine infertility; GSM, gestational surrogate motherhood; IS, immunosuppressive medications; IVF, in vitro fertilization; LDUTx, living donor uterus transplant(ation); RCT, randomized controlled trial; UTx, uterus transplant (ation); VCA, vascular composite allograft Living donor uterus transplantation (LDUTx) allows women without a functional uterus to successfully carry a pregnancy and give birth. In September 2014, the first child was born from a mother affected by absolute uterine infertility (AUI) who had undergone LDUTx (1) . Uterus transplantation (UTx) has been the topic of intense ethical discussions. Poignant points of the ethical discussion are related to the nonlifesaving nature of UTx, the existence of successful alternatives, the experimental nature of UTx, and the risks for the donor. Caplan et al pointed out the different risk-benefit ratio involved in a transplant procedure not meant to be lifesaving but instead meant to be quality-of-life improving and warned about the risk of "therapeutic misconception" for a procedure that is experimental (2) . Similar concepts were raised by Arora and Blake, who called for a greater justification for UTx because of its nonlifesaving nature and because alternatives are available. Nonetheless, they also invoked patients' autonomy in choosing between alternatives, stressing the importance of informed consent and the fact that UTx is experimental, unlike gestational surrogate motherhood (GSM) (3). Dickens discussed the ethics of uterus donation and the familial or social pressure that a related donor may feel or the motivation of an unrelated donor (4). Because UTx is considered a vascular composite allograft (VCA), these ethical concerns have been discussed among members and societies of the transplant community. A guidance document by the Organ Procurement Transplant Network was issued and aims at providing guidance regarding criteria for programs, informed consent recommendations, and donor evaluation (5).
The principle of equipoise has been described as one of the most influential concepts in research ethics (6) . Introduced by Fried to determine the ethical basis on which an individual investigator could enroll patients in randomized controlled trials (RCTs), the concept evolved under Freedman in what is today known as "clinical equipoise" (7, 8) . Clinical equipoise addresses the ethical basis of RCTs, stating that RCTs are ethical only if a genuine state of uncertainty relative to the therapeutic merits of every arm in the trial exists. In other wordss RCT are ethical when there is no consensus in the medical experts' community on whether one treatment for a certain condition is superior to another. Moreover, equipoise is reached when there is balance between the risk of causing unintended harm and the potential benefit to the patients. Freedman stated that "equipoise is an ethically necessary condition in all cases of clinical research" (8) . Before the first US living donor liver transplantation was performed, Singer et al discussed its ethical foundation, introducing the concept of equipoise in clinical transplantation. The authors expanded on the concept of equipoise when applied to transplantation, stating that it could be used also to " . . .demonstrate uncertainty (i.e. neither of the two alternative treatments is clearly superior)," and proposed that equipoise could also be used in nonrandomized designs when clinicians use innovative surgical and medical therapies (9) . About a decade later, Cronin and Siegler introduced the concept of double equipoise, which takes into account not only the recipient's outcome but also the risks incurred by the living donor. The ethical principle is satisfied when a balance is present between the recipient's benefits and the donor's risks (10) .
The analysis of LDUTx according to equipoise is only part of a much broader discussion involving the ethics of UTx. In 2007, Caplan et al wrote that UTx failed the clinical equipoise test beause no live birth had been reported. (2) Now that LDUTx has proved to be successful, we believe that the ethical discussion can move forward and that an equipoise analysis is warranted. Because live birth is the objective of a UTx, for the purpose of this report, the discussion should be limited to LDUTx. In fact, to date there have been no reports of successful live births from the recipient of a deceased donor UTx.
Although adoption is a solution for women affected by AUI, it has profound differences with UTx and GSM inasmuch as adoption does not provide the primary benefit of a genetic link between mother and child and the possibility for a woman to experience the physical and emotional aspects of pregnancy. In most cases, the woman who adopts is physically and temporarily disconnected from the experience. As Cahill stated, "Adoption is usually a measure taken after the facts of conception, pregnancy and birth" (11). Arora and Blake state that the intent of UTx is to produce a child, and this difference with adoption has ethical import (3). For these reasons, the equipoise analysis is limited to LDUTx and GSM.
The ethical debate about GSM is intense, and the procedure is not legal in many countries (12) (13) (14) (15) . Nonetheless, surrogacy is legal in the United States. As such, it is the procedure to which LDUTx must be compared when its merits are analyzed under the equipoise concept. The analysis takes into account the outcome, that is, the birth of a healthy child and the risks incurred by the involved parties, including the LDUTx recipient, the child, the living donor, and the gestational surrogate carrier.
Success of the Procedure
The first question is whether LDUTx is successful in achieving its objective: the delivery of a healthy child by the woman who received a transplant. To date, five of the nine women who underwent LDUTx delivered healthy babies (16) . It may be argued that the success is not 100%. Two women had the transplanted uterus removed, one woman has not been successful in achieving pregnancy, and one woman has not been successful in carrying a pregnancy to term. Nonetheless, five (71.4%) of the seven LDUTx recipients delivered healthy babies. The success of LDUTx compares well with the 46.9% pregnancy and 38.1% live birth rates reported for assisted reproductive technology encompassing all in vitro fertilization (IVF) procedures (17) . When nondonor oocytes (ie, oocytes not from the intended parents) are used in GSM, the rate of clinical pregnancy is 51.8% and that of live births is 41.5%. When donor oocytes are used (oocytes that are neither from the intended parents nor from the gestational carrier), the clinical pregnancy rate is 69.7% and the live birth rate is 60.5% (18) .
Risks to the Mother to Be
IVF risks include side effects of injectable fertility medications (nausea, temporary allergic reactions, breast tenderness and increased vaginal discharge, mood swings and fatigue, or ovarian hyperstimulation syndrome). IVF is a common clinical procedure, and most of the potential side effects are considered mild.
Unique to the woman who undergoes LDUTx are the risks of the operations: the LDUTx itself, the cesarean section to deliver the baby, and the hysterectomy after the delivery. The incidence of surgical complications in LDUTx is still uncertain, while the cesarean section and hysterectomy should not be more complicated than they are in a nontransplanted women. Seven of the nine LDUTx recipients did not experience any immediate surgical complications, and two had a graft hysterectomy: one for thrombosis and the other for infection. It is difficult to draw conclusions about whether the risks of complications for a procedure that is not lifesaving outweigh the benefits, especially when the data are still insufficient and the technical aspects of LDUTx have room for improvement. The worst complication has been the removal of the transplanted uterus, and the women who had the uterus removed have had no physical consequences, although it is possible that the emotional burden will have a long-lasting impact.
A woman undergoing LDUTx will receive immunosuppressive medications (IS) until the uterus is removed. Two orders of risk are associated with IS: one is the commonly known side effects and complications of IS, and the other is the reported increase in pregnancy complications in women taking IS. The IS side effects and complication risks are well known (19) . One important point is that serious side effects like renal dysfunction and hyperglycemia are not manifested until sometime after IS initiation. Becausee LDUTx is temporary and the length of IS therapy is limited, these longterm, serious complications may not manifest as they do in other organ transplant recipients (20, 21) . Another fact is that LDUTx recipients are healthy; they do not have the preexisting health conditions typical of other organ transplant recipients, conditions that IS may exacerbate.
The risk of major obstetric complications during pregnancy is higher in women receiving IS. The risk of preeclampsia is as high as 27% after kidney and 21% after liver transplantations, significantly higher than the 3% rate f preeclampsia in the general population (22) . Organ transplant recipients, though, have a high incidence of comorbidities such as hypertension, from 27% for liver recipients to 54% for kidney recipients, and these comorbidities have a significant causal effect on the incidence of preeclampsia. Gestational diabetes also has a higher incidence: 8% in kidney recipients compared with 4% in the general population (23, 24) .
Despite these increased risks, when a multidisciplinary team is available, most pregnancies are safe and healthy babies are born (25) .
The available data on pregnancy in organ transplant recipients can serve as a valid comparison for LDUTx recipients and a source of information for a proper informed consent.
Risks to the Child
While the incidence of live birth and the risk of miscarriage for recipients of a solid organ transplant are 73.5% and 14%, respectively-similar to the US national average (25), children born from recipients of organ transplants have an increased risk of lower birth weight and preterm delivery. US data show a mean birth weight of 2420 g in children of kidney recipients versus a mean birth weight of 3298 g in the general population and a preterm birth rate of 45.6% in kidney recipients versus 12.5% in the general population (23) . A similar trend is seen in children born from mothers who received a liver transplant (24) . The US National Transplantation Pregnancy Registry has not reported any significant increase or pattern of malformation in children born from mothers taking IS (26) , and the safety of IS during both pregnancy and breastfeeding has been studied (25) .
Less data are available regarding the developmental wellbeing of children born from mothers taking IS. There are studies that link impaired glucose tolerance and ischemic heart disease with low birth weight (27) and animal studies demonstrating that neonatal exposure to cyclosporine in breast milk can cause T cell maturation alterations and mutations (28) . There are also case reports linking autoimmune disease in offspring to immunotherapy exposure in utero (29, 30) .
On the other hand, children born from kidney transplant recipients have a incidence of mental and developmental delay similar to that of the general population, and catchup growth is the norm (30) (31) (32) .
Recipients of organ transplants and LDUTx have in common the need for IS, but preexisting health conditions like hypertension, diabetes, autoimmune diseases, and nutritional deficits are not present in the women undergoing LDUTx. This fact should be taken into account when the incidence of low birth weight, preterm delivery, and immunosuppressive therapy-and their impact on offspring-is considered. In fact, despite five of the LDUTx recipients having preeclampsia and all children being born preterm, the Apgar scores, birth weight, and development of the children have been normal.
Double Equipoise: Benefit to the Recipient and Risks of the Living Donor
LDUTx is not a lifesaving procedure. Its benefits cannot be evaluated in the same terms of longer survival and better quality of life as enjoyed by the recipients of living donor liver or kidney transplants. The risks incurred by the donor should find "justification" in the benefits enjoyed by the recipient. There is no tangible or measurable improvement in life span that is innate to UTx. What LDUTx accomplishes is the natural desire of many women to become a biological mother. LDUTx allows a woman to carry her own pregnancy and to establish a bond with her child from inception. Under this aspect, there is no doubt that the benefits for women with AUI are immense. As pointed out by Orentlicher, the interests of those women who very much want to become mothers through pregnancy should not be dismissed (33) .
The risks to the uterus living donor are similar to those associated with a radical hysterectomy with or without a combined salpingo-oophorectomy. When performed for living donation, these surgeries are more extensive, because the arteries and veins serving the uterus and a rim of vaginal tissue must be preserved. The level of ligation of the internal iliac vessels is similar to that used to control postpartum hemorrhage; therefore, the associated potential complications should also be similar (34) . There are potential risks of injury to the ureter, the iliac vessels, the pelvic nerves, the bladder, and the rectum. Moreover, there are potential risks of decreased quality of life connected to ovarian dysfunction in premenopausal women and potential changes in sexual libido (35, 36) . The data from the Gothenburg series show a very low incidence of complications, although one of the donors did sustain an injury to the ureter that required surgical repair.
One significant difference of donation for LDUTx and for other transplants is that the uterus is not a "vital organ" for the donor; when donated, it has exhausted its function for the woman who donates it. There are no long-term physiologic or health-related issues after hysterectomy, and some women may see a hysterectomy as a prophylactic measure against possible future pathologies. When the mother is the donor to her daughter, an additional benefit is to have directly contributed to the birth of a grandchild.
Risks to the Surrogate Mother
Any woman who decides to become a gestational surrogate carrier accepts all potential risks associated with IVF, pregnancy, delivery, and postpartum issues. It must be pointed out that almost 80% of cycles in gestational surrogacy involve the transfer of two or more embryos and that multiple gestation pregnancies are common and associated with increased risks of hypertensive disorders, gestational diabetes, anemia, hemorrhage, cesarean section, and peripartum hysterectomy compared with single pregnancies (18, 37) .
Conclusions
LDUTx is in its infancy; more experience is necessary to draw definite conclusions, but the present data indicate that, compared with GSM, the basic requirements of the principle of equipoise are fulfilled. LDUTx success in allowing the birth of healthy babies is similar to, if not better than, that reported for GSM. The children of women recipients of LDUTx fare as well as any child born from a mother taking IS and, to date, show no deficits in overall physical and mental development (16) . Arora and Blake pointed out that the well-being of the child must be considered and the risks to the child must be low enough to counterbalance the reproductive interests of the parents (3). In our society, we have not discouraged reproduction in recipients of solid organ transplantation, and their children are the closest comparison to the ones born after LDUTx. Although early in the experience, it is a fact that all children born from LDUTx mothers are absolutely healthy and have not had growth retardation. It seems that with the appropriate prenatal and perinatal care, the risks to these children can be greatly minimized.
LDUTx is an experimental procedure, and informed consent is critical. The risks of LDUTx can be explained to the recipients and the donors, by drawing data from the vast experience in solid organ transplant and obstretics/ gynecology, stressing the fact that their true incidence is not completely known. Farrell and Falcone point out that the importance of a proper informed consent for both the donor and the recipient is central in ensuring that a voluntary choice is made (38) , and Olausson et al write that "the recipient is fully aware of the experimental nature of the procedure" and that the recipient is able to make an independent decision as to whether to participate (39). Catsanos et al suggested that the standard for UTx informed consent should be closer to that of consent to research by healthy volunteers than to that of patients consenting to treatment (40) .
The "unknowns" for the donor hysterectomy are not as significant as the ones for the LDUTx recipient. The loss of the uterus does not constitute the loss of a vital organ and, in the absence of complications, has no potential long-term consequences. Nonetheless, the principle guiding the care for the donor should follow the same principles that have characterized organ living donation and are outlined in the guidance document for VCAs from living donors (5) . The donors must receive full disclosure of the experimental nature of UTx, be aware of alternatives to UTx, and be able to give informed consent. Their decision must be free from coercion. Minimizing risks and respect for donor's autonomy must have the highest priority and, as stated by the Ethics Committee of the Transplantation Society, the aggregate benefits to the donor-recipient pair must outweigh the risks to the donor-recipient pair (41) .
There clearly is an imbalance when comparing the risks of GSM with those of the woman undergoing LDUTx. The latter must undergo at least three surgical procedures and take IS to be able to have a baby. This imbalance has no solution when only the clinical aspects of the comparison are considered. One important point, however, is that the LDUTx recipient accepts all these risks for her natural desire to carry her own pregnancy. Most gestational surrogate mothers assume risks because of the associated financial benefits, not for having their own children.
LDUTx allows women affected by AUI the possibility of having a child. The ethics surrounding this procedure are complex (39, 40, (42) (43) (44) . The question remains whether it is ethical to put two people at risk when performing a UTx when other options are available, including the option of not having a child.
De facto living donor Utx has now become a real option for women with AUI. It is still experimental, but the preliminary results are very promising. At the present time, LDUTx should stand on the ethical principles outlined by Moore for innovative surgeries with an emphasis on "field strength" and a proper and complete informed consent (45) .
Our analysis comparing LDUTx with GSM concludes that, although in its infancy, LDUTx represents a real clinical solution to AUI and is not inferior to GSM when analyzed under the principle of equipoise.
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